Unicycive Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
UNCY Nasdaq 2830 unicycive.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Unicycive Therapeutics, Inc.

Unicycive Therapeutics (UNCY) Pivots From Profit To Loss And Expands Equity Pool Is The Story Changing? - May 14th, 2026 5:19 pm
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - May 12th, 2026 5:05 am
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Apr 9th, 2026 5:05 am
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - Mar 30th, 2026 5:05 am
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - Feb 4th, 2026 5:05 am
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - Jan 29th, 2026 7:15 am
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - Jan 29th, 2026 5:05 am
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - Dec 29th, 2025 5:05 am
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth - Dec 29th, 2025 5:02 am
Unicycive Therapeutics to Participate in Upcoming Investor Events in December - Nov 25th, 2025 5:05 am
Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well - Nov 18th, 2025 4:09 am
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update - Nov 12th, 2025 5:05 am
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference - Nov 3rd, 2025 5:05 am
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference - Oct 30th, 2025 5:05 am
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End - Oct 28th, 2025 5:05 am
When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit? - Oct 14th, 2025 6:46 am
Unicycive Therapeutics to Participate in Upcoming Investor Events in September - Aug 26th, 2025 5:00 am
Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease - Aug 18th, 2025 5:05 am
Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - Aug 14th, 2025 5:00 am
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology - Jul 24th, 2025 6:00 am